L-022-2017

Agreement ID
L-022-2017
Lead IC
NCI
Exclusivity
Exclusive
External Party
Etubics Corporation
Fiscal Year
2017
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4180     Brachyury-directed Vaccine for the Prevention or Treatment of Cancers
TAB-4006     MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors
TAB-5083     Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein